Our FDA‐approved drug screening reveals that abemaciclib, a selective CDK4/6 inhibitor, effectively promotes YAP1 ubiquitination and degradation, thereby inhibiting CRC progression in CDX and PDX models (Figures 1 and S1). This evidence concerns the gene YAP1 and colorectal carcinoma.